“2-deoxy-D-glucose” – DRDO’s Anti-COVID drug
Red Book
Red Book

Pre-cum-Mains GS Foundation Program for UPSC 2026 | Starting from 5th Dec. 2024 Click Here for more information

What is the News?

Recently, the Drugs Controller General of India(DCGI) has approved an anti-COVID drug named 2-deoxy-D-glucose(2-DG). The Defence Research and Development Organization(DRDO) developed this medicine for emergency use.

However, independent experts have raised questions about the efficacy of the drug.

About 2-deoxy-D-glucose (2-DG):
  • 2-DG drug has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS)- a lab of DRDO in collaboration with Dr. Reddy’s Laboratories(DRL).
  • The drug comes in powder form in the sachet. One has to take it orally by dissolving the powder in water.
Working Mechanism of the drug:
  • The basic mechanism of the drug involves inhibiting glycolysis or one of the ways in which cells break down glucose for energy.
  • This approach can starve and kill cancer cells, but in theory, work in inhibiting virus cells too, that are almost entirely dependent on glycolysis for replication.

Questions over 2-deoxy-D-glucose: Independent experts have raised questions over the utility of the drug based on the following reasons:

  • Firstly, lack of published data on its performance in human trials,
  • Secondly, questions on whether the phase-3 trial objectively evaluated the benefits of the drug and its side effects
  • Thirdly, the drug’s history of being an unapproved anti-cancer drug.

Source: The Hindu

Zydus Cadila’s antiviral drug “Virafin” gets emergency use nod


Discover more from Free UPSC IAS Preparation For Aspirants

Subscribe to get the latest posts sent to your email.

Print Friendly and PDF
Blog
Academy
Community